Evidence map›Paper›PMID 35909193›Full record

ArticleArchives of toxicology2022

Assessment of the exposure to polycyclic aromatic hydrocarbons in users of various tobacco/nicotine products by suitable urinary biomarkers.

Gerhard Scherer, Max Scherer, Nadine Rögner, Nikola Pluym

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Gerhard SchererABF, Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstraße 5, 82152, Planegg, Germany. gerhard.scherer@abf-lab.com.ORCID 0000-0001-7456-3402
Max SchererABF, Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstraße 5, 82152, Planegg, Germany.
Nadine RögnerABF, Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstraße 5, 82152, Planegg, Germany.
Nikola PluymABF, Analytisch-Biologisches Forschungslabor GmbH, Semmelweisstraße 5, 82152, Planegg, Germany.
Analytisches Laboratorium · DE

Funding

Foundation for a Smoke-Free World 2018/03
6 · The paper itself

Abstract

Polycyclic aromatic hydrocarbons (PAHs) occur naturally (bitumen and oils) and are formed during all incomplete combustions of organic materials. PAH exposure sources are manifold and include specific workplaces, ambient air, various foodstuffs, tobacco smoke and some medications. At least four members of this class of chemicals have been classified as proven or probable human carcinogens. Assessment of the exposure to PAHs with suitable methods is of importance, particularly in users of new-generation tobacco/nicotine products, which are intended to replace combustible cigarettes (CCs), a major source of non-occupational exposure to PAHs. In a clinical study comprising a period of 74 h under confinement, we investigated the exposure to naphthalene (Nap), fluorene (Flu), phenanthrene (Phe), pyrene (Pyr) and benzo[a]pyrene (BaP) by measuring urinary monohydroxy-PAH (OH-PAH) derived from these parent compounds in habitual users of CCs, electronic cigarettes (ECs), heated tobacco products (HTPs), oral tobacco (OT), and nicotine replacement therapy products (NRTs). Non-users (NU) of any tobacco/nicotine products served as (negative) control group. Smokers exhibited the highest levels for all PAH biomarkers measured, almost all of which were significantly different from the NU and user groups of all other products investigated. CC smokers were the only group which showed a significant relationship between almost all PAH biomarkers and dose markers such as daily consumption, urinary nicotine equivalents (Nequ) and plasma cotinine (CotP). The ratios in urinary OH-PAH between CC and all other groups were dependent on the biomarker and range from < 2 to > 10. These ratios could at least partly be explained by the enzymes involved, their region-selectivity and inducibility by smoking. In conclusion, cigarette smokers (CC) were the only group, which showed product use dependent exposure to PAHs, whereas users of EC, HTP, NRT and OT were not distinguishable from NU of any tobacco/nicotine products.

Indexed as

Electronic Nicotine Delivery SystemsPhenanthrenesPolycyclic Aromatic HydrocarbonsSmoking CessationTobacco ProductsTobacco Smoke PollutionBenzo(a)pyreneBiomarkersCarcinogensCotinineFluorenesHumansNaphthalenesNicotineOilsPyrenesBenzo(a)pyreneBiomarkersCarcinogensCotinineFluorenesNaphthalenesNicotineOilsPhenanthrenesPolycyclic Aromatic HydrocarbonsPyrenesTobacco Smoke PollutionBiomarkers of exposureCombustible cigarettesElectronic cigarettesHeated tobacco productsHydrocarbonsPolycyclic aromaticSnus

Identifiers

PMID35909193
OpenAlexW4289109070

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.